Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Variation in the inhibitory potency of terbinafine among genetic variants of CYP2D6.

Drug metabolism and pharmacokinetics - 1 Aug 2015

Akiyoshi Takeshi, Ishiuchi Miho, Imaoka Ayuko, Ohtani Hisakazu

Abstract excerpt

Cytochrome P450 2D6 (CYP2D6) is a highly polymorphic enzyme that is involved in the metabolism of many drugs. Terbinafine (TER) is a CYP2D6 inhibitor and causes persistent drug interactions in the clinical setting; however, its inhibitory mechanism and the differences in its inhibitory potency among genetic variants of CYP2D6 remain to be investigated. This study aimed to investigate the inhibitory mechanism of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytochrome P-450 CYP2D6
Share to Cytochrome P-450 CYP2D6 Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genetic Variation

Share to Naphthalenes

Source

Identifiers

PMID: 26195224
DOI: 10.1016/j.dmpk.2015.04.003

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Variation in the inhibitory potency of terbinafine among genetic variants of CYP2D6.PMID 26195224Read ↗

Profile of the inhibitory effects of gefitinib on CYP2D6 variants in vitro.Semantic proximity Read ↗

In vitro comparative analysis of metabolic capabilities and inhibitory profiles of selected CYP2D6 alleles on tramadol metabolism.Semantic proximity Read ↗

Comparative metabolic capabilities and inhibitory profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17.Semantic proximity Read ↗

Genotype-sensitive reversible and time-dependent CYP2D6 inhibition in human liver microsomes.Semantic proximity Read ↗

CYP2D6 Allelic Variants *34, *17-2, *17-3, and *53 and a Thr309Ala Mutant Display Altered Kinetics and NADPH Coupling in Metabolism of Bufuralol and Dextromethorphan and Altered Susceptibility to Inactivation by SCH 66712.Semantic proximity Read ↗

Inter-individual variability of in vivo CYP2D6 activity in different genotypes.Semantic proximity Read ↗

Assessment of activity levels for CYP2D6*1, CYP2D6*2, and CYP2D6*41 genes by population pharmacokinetics of dextromethorphan.Semantic proximity Read ↗

Comparison of cytochrome P450 2D6 and variants in terms of drug oxidation rates and substrate inhibition.Semantic proximity Read ↗

Identification and drug metabolic activity evaluation of 12 CYP2D6 allelic variants newly detected in the Chinese population.Semantic proximity Read ↗

Celecoxib is a substrate of CYP2D6: Impact on celecoxib metabolism in individuals with CYP2C9*3 variants.Semantic proximity Read ↗

In vitro functional assessment of 22 newly identified CYP2D6 allelic variants in the Chinese population.Semantic proximity Read ↗

Effects of 22 Novel CYP2D6 Variants Found in the Chinese Population on the Bufuralol and Dextromethorphan Metabolisms In Vitro.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.